219
Participants
Start Date
September 6, 2019
Primary Completion Date
August 31, 2024
Study Completion Date
August 31, 2024
BMS-986288
Specified dose on specified days
Nivolumab
Specified dose on specified days
Regorafenib
Specified dose on specified days
Local Institution - 0011, Ciudad Autónoma de Buenos Aires
Local Institution - 0017, Buenos Aires
Local Institution - 0013, Río Cuarto
Local Institution - 0026, Marseille
Local Institution - 0040, Milan
Local Institution - 0031, Milan
Local Institution - 0002, Baltimore
Local Institution - 0023, Madrid
Local Institution - 0024, Majadahonda
Local Institution - 0034, Bordeaux
Local Institution - 0038, Padua
Local Institution - 0055, Seville
Local Institution - 0022, Saint-Herblain
Local Institution - 0025, Valencia
Local Institution - 0028, Ancona
Local Institution - 0004, St Louis
Local Institution - 0018, Bron
Local Institution - 0015, Paris
Local Institution - 0005, Aurora
Centre Hospitalier intercommunal de Toulon La Seyne sur Mer, Toulon
Local Institution - 0033, Catanzaro
Local Institution - 0075, Costa Mesa
Local Institution - 0010, Viña del Mar
Local Institution - 0036, Santiago
Local Institution - 0019, Santiago
Local Institution - 0035, Santiago
Local Institution - 0009, Santiago
Local Institution - 0050, Orange
Local Institution - 0001, Hackensack
Local Institution - 0074, Buenos Aires
Local Institution - 0014, Córdoba
Local Institution - 0008, ABB
Local Institution - 0012, CABA
Local Institution - 0016, Buenos Aires
Local Institution - 0006, Toronto
Local Institution - 0042, Montreal
Local Institution - 0046, Montreal
Local Institution - 0039, Roma
Local Institution - 0056, Barcelona
Local Institution - 0054, Barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY